Warkentin T E, Elavathil L J, Hayward C P, Johnston M A, Russett J I, Kelton J G
McMaster University, Hamilton Health Sciences Corporation, Ontario, Canada.
Ann Intern Med. 1997 Nov 1;127(9):804-12. doi: 10.7326/0003-4819-127-9-199711010-00005.
Platelet-mediated arterial occlusion is a well-recognized cause of limb loss in patients with heparin-induced thrombocytopenia. However, the syndrome of distal ischemic necrosis complicating the deep venous thrombosis (venous limb gangrene) sometimes associated with heparin-induced thrombocytopenia has not been well characterized.
To study the pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia.
Characterization (based on descriptive and case-control studies) of a novel syndrome of limb loss and hypothesis testing by analysis of plasma samples.
Five university-associated hospitals in one medical community.
Clinical and laboratory records of 158 patients with heparin-induced thrombocytopenia were reviewed to identify patients with venous limb gangrene (n = 8), limb arterial thrombosis (n = 10), and uncomplicated deep venous thrombosis (n = 58).
Clinical and laboratory factors associated with venous limb gangrene, including thrombin-antithrombin complexes and vitamin K-dependent procoagulant and anticoagulant factors.
Warfarin treatment was more frequently associated with venous limb gangrene than with limb arterial thrombosis (8 of 8 patients compared with 3 of 10 patients; P = 0.004). The anticoagulant effect of warfarin seemed greater in the 8 patients with venous limb gangrene than in the 58 patients who did not develop gangrene (median International normalized ratio, 5.8 compared with 3.1; P < 0.001). Compared with plasma from controls, plasma from patients with venous limb gangrene had a higher ratio of thrombin-antithrombin complex to protein C activity during warfarin treatment. No hereditable abnormalities of the protein C anticoagulant pathway were seen in any patient.
Warfarin treatment of deep venous thrombosis associated with heparin-induced thrombocytopenia is a possible cause of venous limb gangrene, perhaps because of acquired failure of the protein C anticoagulant pathway to regulate thrombin generation.
血小板介导的动脉闭塞是肝素诱导的血小板减少症患者肢体丧失的一个公认原因。然而,有时与肝素诱导的血小板减少症相关的远端缺血性坏死并发深静脉血栓形成(静脉性坏疽)综合征尚未得到充分描述。
研究与肝素诱导的血小板减少症相关的静脉性坏疽的发病机制。
对一种新型肢体丧失综合征进行特征描述(基于描述性和病例对照研究),并通过分析血浆样本进行假设检验。
一个医疗社区的五家大学附属医院。
回顾了158例肝素诱导的血小板减少症患者的临床和实验室记录,以确定患有静脉性坏疽的患者(n = 8)、肢体动脉血栓形成的患者(n = 10)和无并发症的深静脉血栓形成的患者(n = 58)。
与静脉性坏疽相关的临床和实验室因素,包括凝血酶 - 抗凝血酶复合物以及维生素K依赖的促凝血和抗凝血因子。
华法林治疗与静脉性坏疽的关联比与肢体动脉血栓形成更为常见(8例患者中有8例,而10例患者中有3例;P = 0.004)。在8例患有静脉性坏疽的患者中,华法林的抗凝作用似乎比58例未发生坏疽的患者更大(国际标准化比值中位数分别为5.8和3.1;P < 0.001)。与对照组血浆相比,在华法林治疗期间,静脉性坏疽患者血浆中凝血酶 - 抗凝血酶复合物与蛋白C活性的比值更高。在任何患者中均未发现蛋白C抗凝途径的遗传性异常。
华法林治疗与肝素诱导的血小板减少症相关的深静脉血栓形成可能是静脉性坏疽的一个原因,可能是由于蛋白C抗凝途径获得性无法调节凝血酶生成。